Table 1

| Study Country, year started, clinical sites, total subjects | Age Mean | Male (%) | Pack years | Current smokers (%) | LDCT screening and control (N) | Follow up (years) | Lung cancers diagnosed (early stage) | Lung cancer mortality | Overall mortality |
|---|-----------------------------|-------------|---------------|---------------------------|---|-------------------------|--|-----------------------------|---------------------------|
| DANTE Italy, 2001 3 sites N = 2,532 | 64.6 | 100 | 45 | 56.9 | LDCT, 5 annual rounds (N = 1300) Control, 5 annual clinical review (N = 1232) | 8.35 | LDCT: 104 (45.2) Control: 72 (22.2) | LDCT: 61 Control: 56 | LDCT: 186 Control: 183 |
| DLCST Denmark, 2004 1 site N = 4,104 | 57.9 | 56 | 36.2 | 76.1 | LDCT, 5 annual rounds (N = 2052) Control, 5 annual health interviews (N = 2052) | 9.8 | LDCT: 100 (50.0) Control: 53 (15.1) | LDCT: 39 Control: 38 | LDCT: 165 Control: 163 |
| ITALUNG Italy, 2004 3 sites N = 3,206 | 60.8 | 65 | 39 | 65 | LDCT, 4 annual rounds (N = 1613) Control, usual care (N = 1593) | 9.3 | LDCT: 67 (35.8) Control: 71 (11.3) | LDCT: 43 Control: 60 | LDCT: 154 Control: 181 |
| US, 2000 6 sites N = 3,318 | | 59 | 54 | 58 | LDCT, 2 annual rounds (N = 1660) Control, CXR, 2 annual rounds (N = 1658) | 5.2 | NA | LDCT: 32 CXR: 26 | LDCT: 139 CXR: 116 |
| LUSI Germany, 2007 1 region N = 4,052 | 55 <u>(</u> med <u>ian)</u> | 64.7 | NA | 61.9 | LCDT, 5 annual rounds (N = 2029) Control, 5 annual surveys (N = 2023) | 8.89 | LDCT: 85 (55.3) Control: 67 (6.0) | LDCT: 29 Control: 40 | LDCT: 148 Control: 150 |
| MILD Italy, 2005 1 site N = 3,446 | 57 | 64.5 | 38 | 89.7 | LDCT, 3 or 5 annual rounds (N = 1723) Usual care (N = 1723) | 9-10 | LDCT: 63 (NA) Control: 60 (21.7) | LDCT: 31 Control: 40 | LDCT: 92 Control: 106 |

| NELSON | 58 | 84 | 38 | 55 | LDCT, 4 annual rounds | NA | NA | NA | LDCT: 904 |
|-------------|------|------|----|------|-------------------------|-----|-------------------|------------|--------------|
| Belgium/ | | | | | (N = 7915) | | | | Control: 934 |
| Netherland, | | | | | Control, no screening | | | | |
| 2003 | | | | | (N = 7907) | | | | |
| 4 sites | | | | | | | | | |
| N = 15,822 | | | | | | | | | |
| NLST | 61.4 | 59.5 | 48 | 48 | LDCT, 3 annual rounds | 6.5 | LDCT: 1060 (49.1) | LDCT: 469 | LDCT: 1912 |
| US, 2002 | | | | | (N = 26,722) | | CXR: 941 (30.7) | CXR: 552 | CXR: 2039 |
| 33 sites | | | | | Control, CXR, 2 annual | | | | |
| N = 53,452 | | | | | rounds (N = 26,730) | | | | |
| Yang | 59.8 | 46.8 | NA | 21.5 | LDCT, 2 biennial rounds | 2 | LDCT: 48 (NA) | LDCT: 0 | NA |
| China, 2013 | | | | | (N = 3,512) | | Control: 2 (NA) | Control: 2 | NA |
| 1 site | | | | | Control, standard care | | | | |
| N = 6,657 | | | | | (N = 3,145) | | | | |